Michael Slezak writes (8 March, p 40) that in New Zealand’s assessment of harm from novel drugs, reports of “cramp, unconsciousness or hallucinations score 2; coma, paralysis or deafness score 3. Any product that accumulates a score of more than 2 per 20,000 units sold is taken off the market”. For some drugs, failing to produce hallucinations would lead to them being taken off the market under trade description rules.
I have some recollection – from youthful experimentation, Your Honour – that hallucinations were frequently the entire point.
Name and address supplied
